ANI Pharmaceuticals, Inc.(ANIP)
Pharmaceuticals
Specialty Pharma
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale | -500 | -0.64%77,890 | $82.03 | $41,015 | View SEC filing | |
| 2026-06-10 | HAUGHEY THOMAS Director | Sale | -2,000 | -4.89%38,878 | $80.88 | $161,760 | View SEC filing | |
| 2026-06-09 | CAREY STEPHEN P. SVP & CFO | Sale | -3,312 | -1.80%180,393 | $80.00 | $264,960 | View SEC filing | |
| 2026-05-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale | -500 | -0.63%78,390 | $78.16 | $39,080 | View SEC filing | |
| 2026-05-13 | Gutwerg Ori SVP, GENERICS | Sale | -2,772 | -3.40%78,696 | $79.50 | $220,374 | View SEC filing | |
| 2026-05-13 | Lalwani Nikhil PRESIDENT & CEO | Sale | -55,000 | -13.58%349,889 | $77.57 | $4,266,350 | View SEC filing | |
| 2026-05-13 | Walsh Patrick D Director | Sale | -13,973 | -26.66%38,432 | $80.66 | $1,127,120 | View SEC filing | |
| 2026-05-13 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Sale | -459 | -1.19%38,271 | $79.21 | $36,357 | View SEC filing | |
| 2026-04-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale | -500 | -0.63%78,890 | $77.95 | $38,975 | View SEC filing | |
| 2026-03-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale | -500 | -0.63%79,390 | $72.62 | $36,310 | View SEC filing | |
| 2026-03-13 | Mutz Christopher HEAD OF RARE DISEASE | Sale | -3,162 | -3.35%91,309 | $71.64 | $226,526 | View SEC filing | |
| 2026-03-13 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Sale | -4,772 | -10.97%38,730 | $74.91 | $357,471 | View SEC filing | |
| 2026-03-10 | Davis Krista SVP, CHIEF HR OFFICER | Sale | -6,572 | -11.23%51,946 | $74.33 | $488,474 | View SEC filing | |
| 2026-03-10 | Mutz Christopher HEAD OF RARE DISEASE | Sale | -5,723 | -8.73%94,471 | $74.19 | $424,617 | View SEC filing | |
| 2026-03-05 | CAREY STEPHEN P. SVP & CFO | Sale | -7,312 | -3.79%185,543 | $75.50 | $552,031 | View SEC filing | |
| 2026-03-04 | Mutz Christopher HEAD OF RARE DISEASE | Sale | -417 | -0.40%103,508 | $74.00 | $30,858 | View SEC filing | |
| 2026-03-04 | Gutwerg Ori SVP, GENERICS | Sale | -2,060 | -2.37%84,782 | $76.50 | $157,590 | View SEC filing | |
| 2026-03-03 | Walsh Patrick D Director | Sale | -6,000 | -10.27%52,405 | $74.23 | $445,380 | View SEC filing | |
| 2026-02-23 | Davis Krista SVP, CHIEF HR OFFICER | Sale | -3,814 | -7.19%49,263 | $77.74 | $296,495 | View SEC filing | |
| 2026-02-23 | Mutz Christopher HEAD OF RARE DISEASE | Sale | -5,323 | -5.90%84,840 | $78.02 | $415,300 | View SEC filing | |
| 2026-02-17 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale | -500 | -0.72%69,329 | $76.80 | $38,400 | View SEC filing | |
| 2026-02-17 | Mutz Christopher HEAD OF RARE DISEASE | Sale | -7,032 | -7.06%92,566 | $76.55 | $538,300 | View SEC filing | |
| 2026-01-14 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale | -500 | -0.67%74,374 | $84.33 | $42,165 | View SEC filing | |
| 2025-12-19 | Davis Krista SVP, CHIEF HR OFFICER | Sale | -1,622 | -2.69%58,564 | $82.40 | $133,653 | View SEC filing | |
| 2025-12-12 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale | -400 | -0.53%74,874 | $82.32 | $32,928 | View SEC filing |
1-25 of 253